Public Company Information:
SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that Paul C. Grint, M.D., Chief Executive Officer, will present a company overview at the LD Micro 10th Annual Main Event, on Tuesday, December 5, 2017, at 10:30 a.m. PST (1:30 p.m. EST), in Los Angeles.
The presentation will be available on the Events and Presentations page in the Investor Relations section of AmpliPhi’s website at www.ampliphibio.com.
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology. AmpliPhi’s lead product candidates target multidrug-resistant Staphylococcus aureus and Pseudomonas aeruginosa, which are included on the WHO’s 2017 Priority Pathogens List. Phage therapeutics are uniquely positioned to address the threat of antibiotic-resistance as they can be precisely targeted to kill select bacteria, have a differentiated mechanism of action, can penetrate and disrupt biofilms (a common bacterial defense mechanism against antibiotics), are potentially synergistic with antibiotics and have been shown to restore antibiotic sensitivity to drug-resistant bacteria. For more information visit www.ampliphibio.com.
At the Company:
Matthew Dansey, (858) 800-4869
Robert H. Uhl, (858) 356-5932
Russo Partners, LLC
David Schull or Maggie Beller, (212) 845-4271